In this study, we demonstrated that elevated Cyfra21-1 and advanced clinical stage were independently associated with shorter DFS and OS in EGFR-mutated adenocarcinoma patients, while increased CEA and advanced clinical stage were independently associated with worse DFS and OS in wild-type adenocarcinoma patients. This evidence concerns the gene CEACAM5 and adenocarcinoma.